The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. - Wikidata - awgldk - TriplyDB

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

http://www.wikidata.org/entity/Q35000726

about

Thunder and lightning: immunotherapy and oncolytic viruses collide Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines Dendritic-Tumor Fusion Cell-Based Cancer Vaccines Immune Cells in Cancer Therapy and Drug Delivery Targeted immunotherapy for pediatric solid tumors Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer Dendritic cell-based cancer immunotherapy for colorectal cancer Cancer immunotherapy: the beginning of the end of cancer?Dendritic cell-based vaccine for pancreatic cancer in Japan Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents Applying the Analytic Hierarchy Process in healthcare research: A systematic literature review and evaluation of reporting Synthetic self-adjuvanting glycopeptide cancer vaccines Immunotherapy of Childhood Sarcomas Molecular Targeted Intervention for Pancreatic Cancer Antibody-drug conjugates as novel anti-cancer chemotherapeutics Adoptive T-cell therapy for cancer: The era of engineered T cells Molecular recognition of gangliosides and their potential for cancer immunotherapies Duality of the immune response in cancer: lessons learned from skin Role of non-classical MHC class I molecules in cancer immunosuppression Adoptive T-cell therapy for Leukemia Cancer vaccines Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials Glycotherapy: new advances inspire a reemergence of glycans in medicine A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect Quantifying biomass changes of single CD8+ T cells during antigen specific cytotoxicity Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.Mucins in neoplasms of pancreas, ampulla of Vater and biliary system Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins DNA vaccine for cancer immunotherapy T-cell receptor gene therapy--ready to go viral?TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study Theranostic impact of NG2/CSPG4 proteoglycan in cancer Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC)Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation

P2860

Q24597894-5B7A7785-1AB4-47F4-A2EC-9BAFDF4E8DB9 Q26740513-E666B736-4C7C-4DC2-9AAC-2831DA3E2EB9 Q26744827-2352F5AB-8FA6-4E8B-9AE4-7715B2DBD904 Q26747061-9135F92D-5F40-4F2A-BFCA-F5DF20161B30 Q26747703-FF79272B-E598-48A6-9754-55342B7761E2 Q26748727-2635808A-E3E1-490A-A6C6-F69D273B1C18 Q26749451-4199AAF7-17FD-452A-B2D7-CA7B906D6530 Q26751339-8588F1FE-AF1D-4581-90E1-BC150724CCC7 Q26752277-1530F78A-A651-4D8D-9F48-96E47A3D0FE7 Q26768252-DAFC4258-474A-4898-80FF-3C8F0E047B25 Q26771367-B963A4F6-BE54-4D88-94C2-964725C83A4F Q26772051-F8282A4A-AE66-49C8-A1C4-5A576DD93924 Q26777837-5D6F16B8-121D-461B-81C0-1DEB8F73C819 Q26795369-DE026384-D7A3-47EB-97EC-FC1BE858F11E Q26798453-EE7A8EE5-A212-4AA5-BE0B-6D51B6C57AFC Q26800175-B5517556-5B4C-44EB-8265-DB1100CB9E2D Q26800611-FDD1DE9D-E88A-46C8-9389-9C652BBFE3CE Q26830588-E8D20AB6-E130-42F6-955A-591C72C85254 Q26999379-13B7287D-30BB-44AE-8436-94A6A8BA6C7A Q26999722-68D8CAED-A0C1-4A59-821F-94EA44231A45 Q27006934-D5CCE603-12D9-43DC-8FD3-8EFB102E5A9D Q27024438-2488FE9D-EFFF-429E-AE5C-DC1CB8133B9F Q27025832-22B0BC29-1BEC-42B7-A354-2305FA0F004A Q27026836-6A53C300-FC84-4672-B319-6403FA5CCBAF Q27027997-D6C483DD-34D6-4839-9BB3-48B8BECEF085 Q27300754-5E04B658-7980-4DA1-8FA8-983150274838 Q27311367-B2863FD4-7C02-467D-B9BB-3E739F1A0462 Q27313856-D09FDC0A-D2E2-4189-9F4E-C4940349A641 Q28070355-1567D0EE-34C7-4E70-80E1-3EA9CC661B4F Q28071998-3D72A63C-1A04-42F9-BC86-8A0879921D61 Q28077999-8623E1B7-DDD9-44C4-81DC-C0DE330853DF Q28080919-0DE24D8C-1A65-4ED2-9609-DEFE2CD49DB7 Q28081611-93C68BA8-6AF6-4205-9706-DA2E6ABF1088 Q28081699-61684BF2-7B97-461E-8993-6388496F254E Q28082487-C7F76C74-1B36-410E-970A-7700444FA778 Q28084489-1CD7BD9F-C030-49A0-A2A1-7BC1DDBDB2B7 Q28085331-76CFA8FC-DA21-45F7-A25B-FC13B20CCBD4 Q28087470-2F893A14-5D48-4EB1-AA43-2A9666B33075 Q28278814-AE2AE04F-28EB-4EE6-9ABC-387BF211F1AE Q28394194-0712AC7A-0C06-47F7-AD05-1809F8879309

P2860

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

http://www.wikidata.org/entity/Q35000726

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

The prioritization of cancer a ...... ion of translational research.

@ast

The prioritization of cancer a ...... ion of translational research.

@en

type

label

The prioritization of cancer a ...... ion of translational research.

@ast

The prioritization of cancer a ...... ion of translational research.

@en

prefLabel

The prioritization of cancer a ...... ion of translational research.

@ast

The prioritization of cancer a ...... ion of translational research.

@en

P1433

Q35000726-2FF6E62A-EE61-4807-9EA2-F96AFD5CB0DB

P1476

Q35000726-D05CFC45-F8DA-401D-A96D-E1C0989DE936

P2093

Q35000726-08D9A311-7268-4A66-922F-CBC1F6AEC120

Q35000726-109E7BFB-C482-4238-85ED-CF93F53253C4

Q35000726-27B0DF88-7C61-4055-A5FE-B42B58BCD4DC

Q35000726-3A6E5CFD-3815-4357-B528-37C2FE69ADA8

Q35000726-50A3408C-E5D7-4F31-BE23-D82AD3EB00F0

Q35000726-5C850FF6-ED75-48F8-8E18-9999AB6F31BA

Q35000726-9BD4982C-014A-490E-BF66-7FFE7E624CB7

Q35000726-ACF770AC-D9C7-4E27-92EF-0210A238D501

Q35000726-C2FA0A13-037D-4C7B-9AC6-9A1336394625

Q35000726-FC8FE975-3C67-4256-87C8-CE2F78DEA5CD

P2860

Q35000726-004B4911-B16B-4533-9FFB-79A5F3914F20

Q35000726-1182520C-4E8F-4A86-9266-D3F2F5E23BD5

Q35000726-1313586D-9555-452D-B244-90D5F8510F2A

Q35000726-15E08411-C48B-4AA8-9DBF-C149DA8907AF

Q35000726-15FD1894-B8E5-48D6-B844-50F715EA85B3

Q35000726-1DEC93EF-6ADA-48AB-8F1A-D0FBC1C3C966

Q35000726-1E726382-61F9-4D7F-98C0-010132EBB03E

Q35000726-1EA3C88A-C972-4A5C-A93A-27D2E28FCC64

Q35000726-1F232C90-472C-402A-A585-04277890DD10

Q35000726-21638E56-1858-4D55-BF76-A7FE5CABD268

P304

Q35000726-74753EF8-C4B9-4BCC-9C3C-530512453DFC

P31

Q35000726-AB27B616-A06F-43FD-8930-DCA02B32E360

P356

Q35000726-EF09C32D-47D8-4766-A82C-EB42D39E4976

P407

Q35000726-B63EF54C-4E1D-43AB-A559-5A3DD81087DB

P433

Q35000726-256A41FF-9B4A-4C45-BD70-2FCF47C12641

P478

Q35000726-E9AB380A-81A8-4726-B9F4-055B2BCC971E

P50

Q35000726-FE42F05A-2600-4E43-BF04-493E03623DF8

P577

Q35000726-922A27CD-C358-488F-BA5E-49BAABA2E358

P698

Q35000726-5F796092-9AC3-4EA1-B783-AF4822E31D3D

P932

Q35000726-608E14B0-F8C4-49F2-8D6F-79C6F8B1CB0C

P356

1078-0432.CCR-09-0737

P1433

Clinical Cancer Research

P1476

The prioritization of cancer a ...... ion of translational research.

@en

P2093

Andrea S Ferris

http://www.w3.org/2001/XMLSchema#string

Benjamin M Hastings

http://www.w3.org/2001/XMLSchema#string

Ira Mellman

http://www.w3.org/2001/XMLSchema#string

Jaye L Viner

http://www.w3.org/2001/XMLSchema#string

Louis M Weiner

http://www.w3.org/2001/XMLSchema#string

Lynn M Matrisian

http://www.w3.org/2001/XMLSchema#string

Martin A Cheever

http://www.w3.org/2001/XMLSchema#string

Olivera J Finn

http://www.w3.org/2001/XMLSchema#string

Sheila A Prindiville

http://www.w3.org/2001/XMLSchema#string

Toby T Hecht

http://www.w3.org/2001/XMLSchema#string

P2860

Role of the TMPRSS2-ERG gene fusion in prostate cancer

A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication

Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells.

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.

Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases.

Humoral immune responses to testis antigens in sera from patients with prostate cancer.

Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.

PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses

P304

5323-5337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-0737

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

James P. Allison

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19723653

http://www.w3.org/2001/XMLSchema#string

P932

5779623

http://www.w3.org/2001/XMLSchema#string